Duncan NRI Matthew Torre, M.D.
Research focus
Chemotherapy-related cognitive impairment, iatrogenic neuropathology, neurodegeneration
Get to know Matthew Torre, M.D.
Chemotherapy-related cognitive impairment (CRCI) is an increasingly recognized adverse effect of treatment and is observed in up to 75% of patients. Despite the high frequency of CRCI and its associated patient morbidity, the pathophysiology of CRCI is incompletely understood. However, CRCI and neurodegenerative disorders such as Alzheimer's disease plausibly share biological mechanisms, and prior chemotherapy exposure may mediate future risk of dementia. The goal of the Torre laboratory is to dissect mechanisms contributing to CRCI and neurodegeneration and develop therapeutic strategies to preserve cognition in patients at risk of cognitive decline. The laboratory performs studies in complementary organismal model systems, including Drosophila and murine models, and human brain tissue.
Alzheimer's Association Clinician Scientist Fellowship (2023)
Richard L. Davis Award, American Association of Neuropathologists (2023)
Brigham Research Institute Microgrant (2022)
NIH Ruth L. Kirschstein Postdoctoral Individual National Research Service Award (2021)
Torre M, Bukhari H, Nithianandam V, Zanella CA, Mata DA, Feany MB. A Drosophila model relevant to chemotherapy-related cognitive impairment. Sci Rep. 2023 Nov 7;13(1):19290.
Torre M, Dey A, Woods JK, Feany MB. Elevated Oxidative Stress and DNA Damage in Cortical Neurons of Chemotherapy Patients. J Neuropathol Exp Neurol. 2021 Aug 11;80(7):705-712.
Torre M, Feany MB. Iatrogenic Neuropathology of Systemic Therapies. Surg Pathol Clin. 2020 Jun;13(2):331-342.
For a complete list of publications, see: https://www.ncbi.nlm.nih.gov/myncbi/mathew.torre.1/bibliography/public/